VitD: Vitamin D Supplementation and Metabolism in Vitamin D Deficient Elderly

Sponsor

Baltimore VA Medical Center (U.S. Fed)

Overall Status

Terminated

CT.gov ID

NCT01145703

Collaborator

National Institute on Aging (NIA) (NIH), Nutrition Obesity Research Center (NORC) (Other)

Enrollment

Location

Arms

33.1

Duration (Months)

1.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to examine the effects of Vitamin D supplementation on the reasons (mechanisms) underlying the development of type 2 diabetes, metabolic syndrome (high blood pressure, cholesterol, diabetes, body weight/obesity), muscle weakness and wasting (sarcopenia), and impaired physical function (poor balance and walking) associated with vitamin D deficiency and osteopenia/osteoporosis (bone loss). The investigators obtain vitamin D through our diet and sunlight, and its conversion to active vitamins in the liver and kidneys promotes the intestinal absorption of calcium and regulation of bone growth. Therefore, vitamin D deficiency has been known for years to lead to weakened bones (osteopenia and osteoporosis). However, more recently, studies show vitamin D deficiency is associated with a number of other diseases, including type 2 diabetes, muscle weakness, frailty, and the metabolic syndrome. It has also been associated with cognitive impairment. Diabetes affects multiple organ systems including the heart, kidneys, musculoskeletal and nervous system. The possibility that vitamin D deficiency is linked to the development of type 2 diabetes, metabolic syndrome, muscle weakness and wasting (sarcopenia) and osteopenia/osteoporosis, and that vitamin D supplementation decreases the risk for these diseases, provides a relatively easy/accessible and inexpensive model of preventive therapy to decrease the incidence of these diseases. In addition, it is likely that genetic (inherited) factors play a role, but the relationship of these genes to these metabolic abnormalities have not been elucidated. Understanding the role of Vitamin D in health will allow us to translate these findings into therapy.

Condition or Disease	Intervention/Treatment	Phase
Vitamin D Deficiency Metabolic Syndrome	Dietary Supplement: RDA Vitamin D3 only Dietary Supplement: Vitamin D2/3 Repletion only Other: Vitamin D2/3 Repletion + AEX Other: Vitamin D2/3 Repletion + RT	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

39 participants

Allocation:

Randomized

Intervention Model:

Factorial Assignment

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

Effects of Vitamin D Supplementation With and With Out Exercise on Metabolic and Physical Consequences of Vitamin D Deficiency in the Elderly

Study Start Date :

May 1, 2010

Actual Primary Completion Date :

Feb 1, 2013

Actual Study Completion Date :

Feb 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: RDA Vitamin D	Dietary Supplement: RDA Vitamin D3 only 800 IU of Vitamin D3 daily for 6 months Other Names: ergocalciferol
Experimental: Vit D repletion + 6M Supplementation	Dietary Supplement: Vitamin D2/3 Repletion only Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily Other Names: cholecalciferol ergocalciferol
Experimental: Vit D repletion + 6M Supplementation +AEX	Other: Vitamin D2/3 Repletion + AEX Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training Other Names: cholecalciferol ergocalciferol
Experimental: Vit D repletion + 6M Supplementation +RT	Other: Vitamin D2/3 Repletion + RT Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training Other Names: cholecalciferol ergocalciferol

Outcome Measures

Primary Outcome Measures

glucose tolerance and insulin sensitivity [Baseline, 3 months and 6 months]

Secondary Outcome Measures

muscle structure, inflammation and metabolic function to cause sarcopenia and frailty [Baseline, 3 months and 6 months]
physical performance, balance and strength to increase strength and balance to reduce fall risk in older people [Baseline, 3 months and 6 months]
cognitive function [Baseline, 3 months and 6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years to 85 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

40-85 years of age
Women must be post menopausal (absence of menses for 12 months or greater)
25-hydroxyvitamin D level below 20 ng/ml (50 nmol/L)
BMI 25-45 kg/m2
Non smoker ( non smoking for at least 12 months:cigarettes, cigars, pipes)

Exclusion Criteria:

Symptomatic heart disease, CAD, CHF, or uncontrolled hypertension (BP over 180 mm HG) unless medically stabilized
Currently being treated for active cancer
Type 1 diabetes; insulin treatment for diabetes, poorly controlled diabetes, HgA1c

10%

Allergic to lidocaine
History of seizures or taking anti-seizure or anti convulsion medications
Untreated dyslipidemia with National Cholesterol ATPIII 10 year cardiac risk score greater than 10% (www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm)
Taking oral steroids, warfarin or other medications interfering with fat/muscle metabolism that may not be safely discontinued temporarily for specific procedures (ie for 72 hours prior)
Taking medication that interfere with ability to replete Vitamin D
Abnormal liver function 2 times normal levels
Abnormal renal function (BUN above 40 mg/dl, Cr above 1.8 mg/dl, CrCl<60mg/dl)
Hypercalcemia (Ca>10.2mg/dl)
Anemia HCT below 30 mg/dl, platelets below 100,000/cm3
Chronic pulmonary disease (on supplemental O2)
Other systemic disorders that are not medically treated and stable or affect the ability to absorb Vitamin D.
MMSE below 24, dementia or unstable clinical depression by exam
Abnormal response to exercise test (ST segment depression greater than 2mm, chest pain, significant arrhythmias, extreme shortness of breath, cyanosis, exercising BP above 240/120 mm HG, or other contraindications to exercise) *requires follow up treatment w/ primary MD for continued participation in study
Aerobically trained with VO2max greater than 2 SD above age-adjusted mean
Participant is, in the opinion of the investigator, unable to adhere to the study protocol due to medical or orthopedic conditions that limit ability to exercise or travel to the Baltimore VA for protocol procedures.